Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2026)

Xeris Biopharma Holdings has reported Non-Current Assets for 7 years, with the latest figure at $140.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 7.65% year-over-year to $140.3 million; the trailing twelve-month figure through Mar 2026 stood at $578.8 million (down 7.69% YoY), and the FY2025 full-year result was $143.2 million, down 7.84% from the prior year.
• Non-Current Assets for Q1 2026 stood at $140.3 million, down from $143.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $173.0 million in Q2 2023, with the low at $140.3 million in Q1 2026.
• Historically, Non-Current Assets has averaged $156.7 million across 5 years, with a median of $157.4 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 2135.57% — and 2025, when it retreated 7.84%.
• Xeris Biopharma Holdings' Non-Current Assets stood at $157.7 million in 2022, then increased by 5.47% to $166.3 million in 2023, then dropped by 6.58% to $155.4 million in 2024, then slipped by 7.84% to $143.2 million in 2025, then retreated by 2.01% to $140.3 million in 2026.
• The last three Non-Current Assets figures came in at $140.3 million (Q1 2026), $143.2 million (Q4 2025), and $146.2 million (Q3 2025), per Business Quant data.